BNB Attracts Corporate Investment as Biotech Firm Commits $700M
Nasdaq-listed Windtree Therapeutics is making headlines after announcing plans to allocate up to $700 million into Binance Coin (BNB), following the token’s recent all-time high. The Pennsylvania-based biotech company, trading under the ticker WINT, said Thursday that it aims to boost its BNB holdings as part of a broader crypto treasury strategy.
Windtree initially planned a $200 million investment but is now raising an additional $520 million to expand its purchase. The capital will come from a $500 million equity line of credit with an undisclosed institutional investor, and a $20 million stock agreement with Build and Build Corp. The firm also confirmed it will partner with Kraken to securely custody the BNB assets.
“Our strategy depends on securing further funds to invest in BNB, pending shareholder approval,” said CEO Jed Latkin in a release.
BNB, the fifth-largest cryptocurrency by market cap, peaked this week at $808 before retreating to around $769, per CoinGecko data. With a current valuation of $106.9 billion, BNB is the native token of BNB Chain, a blockchain launched by Binance for decentralised applications.
Windtree’s move places it among a growing list of publicly traded firms shifting towards digital assets, not just Bitcoin. Its stock has risen 162% over the last month, though it slipped 5% on Friday.
This trend mirrors the blueprint set by Strategy (formerly MicroStrategy), which holds over 607,000 BTC. Others like Nano Labs, Semler Scientific, Metaplanet, and Classover are also investing heavily in crypto assets like Solana, Ethereum, and XRP to diversify their corporate treasuries and attract investor interest.
